Boston Scientific will buy Penumbra for $14.5 billion, or $374 a share, expanding its cardiovascular reach. Penumbra stock ...

Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...

Boston Scientific to acquire thrombectomy firm Penumbra for $14.5bn, expanding its cardiovascular portfolio as deal reshapes ...

Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a ...

Boston Scientific (NYSE:BSX) today announced a definitive agreement to acquire cardiovascular disease treatment device maker Penumbra.

In a bold move to expand its cardiovascular portfolio, Boston Scientific Corporation has announced its acquisition of Penumbra, Inc. This strategic partnership, valued at approximately $14.5 billion, ...

Ernest Bennin grew up in Ghana and now does research on fast, reliable detection systems that protect soldiers and civilians ...

Hostile racism, such as overt, aggressive and demeaning racial encounters, is significantly associated with increased ...

Last fall Matt Lehman bet a horse at Keeneland that left the gate at 21-1 and won, but then paid 8-1. Now the Kentucky state ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary ...

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical ...